Clear Evidence of the Existence of Healthy Carriers of Hepatitis C Virus Among Renal Transplant Recipients

Haem, J.; Berthoux, P; Jf, Mosnier; Grattard, Florence; Cecillon, S; Pozzetto, Bruno; Alamartine, Éric; Berthoux, F

doi:10.1097/00007890-199609150-00030

Cited by 20 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is no direct answer to this question yet. Some studies have reported a better outcome in transplanted patients, 8,9 while others have shown the opposite results 30 or the same outcome between the two groups 20,31 . It seems further studies are required to answer this question.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Pretransplant hepatitis C virus infection and its effect on the post‐transplant course of living renal allograft recipients

Einollahi¹,

Hajarizadeh

Siamak³

et al. 2003

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

“…Some studies have reported a better outcome in transplanted patients, 8,9 while others have shown the opposite results 30 or the same outcome between the two groups. 20,31 It seems further studies are required to answer this question. However, transplantation is more often considered because of the quality of life improvements.…”

Section: Discussionmentioning

confidence: 99%

Pretransplant hepatitis C virus infection and its effect on the post‐transplant course of living renal allograft recipients

Einollahi¹,

Hajarizadeh

Siamak³

et al. 2003

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…In fact, there is clear evidence of the existence of HCV healthy carrier status following renal transplantation. For example, in one study, about 20% of the renal transplant recipients with chronic HCV infection were considered to be healthy HCV carriers because they had persistent active HCV infection (demonstrated by the presence of HCV RNA in successive serum samples), consistently normal serum ALT levels on consecutive tests and normal histology on liver biopsy performed after at least 2 years followup (7). In these cases, viral replication probably occurs at extrahepatic sites in the absence of any apparent liver involvement.…”

Section: Serum Alanine Aminotransferase (Alt) Levelsmentioning

confidence: 99%

Management of Hepatitis C Infection in Renal Transplant Recipients

Natov

Pereira

2002

American Journal of Transplantation

View full text Add to dashboard Cite

“…Nevertheless, 20–51% of HCV‐positive kidney transplant patients may have normal transaminase levels, although this does not necessarily mean a normal histology [4]. In any case, the state of the healthy carrier, with normal transaminase levels, a positive HCV RNA and a normal histology, has also been described in up to 10% of anti‐HCV positive kidney transplant patients [21].…”

Section: Introductionmentioning

confidence: 99%

Transplantation in the patient with hepatitis C

Domínguez‐Gil¹,

Morales²

2009

Transplant International

View full text Add to dashboard Cite

Summary Hepatitis C virus (HCV) infection is the most frequent cause of liver disease after renal transplantation. Its clinical course is irrelevant in the short term, except for rare cases of fibrosing cholestatic hepatitis. However, in the long run, HCV infection can lead to major liver complications. Because interferon (IFN) is generally contraindicated in renal transplant patients, the best approach is to treat patients on dialysis. Until more information with pegylated‐IFN is available, the use of alpha‐IFN monotherapy is recommended. Most of the patients with sustained virological response remain HCV RNA negative after transplantation. HCV‐positive renal transplant patients have a higher risk for proteinuria, chronic rejection, infections and post‐transplant diabetes (PTDM). Long‐term patient‐ and graft‐survival rates are lower in HCV‐positive patients. Mortality is higher, mainly as a result of liver disease and infections. HCV can contribute to the development of certain neoplasias such as post‐transplant lymphoproliferative disease (PTLD). HCV infection is also an independent risk factor for graft loss. PTDM, transplant glomerulopathy and HCV‐related glomerulonephritis can contribute to graft failure. Despite this, transplantation is the best option for end‐stage renal disease in HCV‐positive patients. Several measures to minimize the consequences of HCV infection have been recommended. Adjustment of immunosuppression and careful follow up in the outpatient clinic for early detection of HCV‐related complications are mandatory.

show abstract

Clear Evidence of the Existence of Healthy Carriers of Hepatitis C Virus Among Renal Transplant Recipients

Cited by 20 publications

References 12 publications

Pretransplant hepatitis C virus infection and its effect on the post‐transplant course of living renal allograft recipients

Pretransplant hepatitis C virus infection and its effect on the post‐transplant course of living renal allograft recipients

Management of Hepatitis C Infection in Renal Transplant Recipients

Transplantation in the patient with hepatitis C

Contact Info

Product

Resources

About